Cincinnati Children's Hospital Medical Center

Medizinische Hochschule Hannover

Westfaelische Wilhelms-universitaet Muenster

Westfalische Wilhelms-universität Münster

Bruce C Trapnell

Takuji Suzuki

Lee A Denson

Axel Schambach

Tony Sallese

Jan Däbritz

Nico Lachmann

Brenna Carey

Thomas Moritz

The disclosure provides compositions and methods for cell therapy of hPAP in humans using gene corrected and in vitro differentiated patient autologous macrophage cells. The disclosure also provides compositions in the form of a cell product and related compositions and methods for making the cell product and for direct pulmonary transplantation of same.

Cell therapy with lentiviral transduced CSF2RA transgene in the treatment of hereditary pulmonary alveolar proteinosis

Disclosed are compositions and methods for treating a condition characterized by a dysregulation in macrophage lipid homeostasis. The disclosed methods may include the administration of an agent selected from a PPAR&#x3b3; agonist, a LXR agonist, or a combination thereof. In certain aspects, the disclosed methods may be used to prevent, treat, or ameliorate conditions such as pulmonary alveolar proteinosis (PAP) and/or symptoms associated therewith.

Composition and methods for treatment of lung disorders characterized by cholesterol dysregulation

Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject.

Methods and compositions for determining and treating relapse in inflammatory bowel disease

Growing community of inventors

Liberty Township, OH, United States of America

Bruce C Trapnell